Hepatitis C virus and Human Immunodeficiency Virus coinfection among attendants of Voluntary Counseling and Testing Centre and HIV follow up clinics in Mekelle Hospital

Department of Microbiology, Immunology and Parasitology, School of Medicine, Addis Ababa University, Ethiopia.
Pan African Medical Journal 03/2013; 14:107. DOI: 10.11604/pamj.2013.14.107.2302
Source: PubMed


Hepatitis C virus remains a large health care burden to the world. HIV and HCV coinfection is major global health concern worldwide. However, there is limited information on the prevalence of HCV/HIV co-infection in Ethiopia. The aim of the study was to assess the magnitude of HIV/HCV coinfection and the potential risk factors in attendants of voluntary counseling and testing centre and HIV follow up clinics of Mekelle hospital.
A cross sectional seroprevalence survey of HCV infection was carried out on 300 HIV negative and positive subjects attending voluntary counseling and testing (VCT) center and HIV follow up clinics of Mekelle hospital, Ethiopia from December 2010-February 2011. Serum samples were tested for anti-HCV antibodies using immunochromatographic test.
Of the 300 study participants, 126(42%) were HIV negative and 174(58%) HIV seropositive from VCT and HIV follow up clinics, respectively. The overall anti-HCV prevalence was 18(6.0%). There were no significant differences in HCV seroprevalence among the different categories of age and sex (p> 0.05). Of the 174 persons with HIV, 16 (9.2%) cases had antibodies to HCV, where as among 126 HIV negative subjects 2 (1.58%) were HCV seropositive (p= 0.006, OR= 6.28, 95% CI= 1.42-27.82).
Accordingly, there was a significant difference in sero-positivity of HCV between HIV positive and HIV negative participants. No apparent risk factor that caused HCV infection was inferred from this study.


Available from: Solomon Gebre-Selassie, Jan 28, 2014
  • Source
    • "In a study of 378 HIV positive individuals in Nairobi, Kenya 6% were co-infected with HBV while 1% was co-infected with HCV [18]. While in a cohort of 138 HIV positive patients in Ghana HBV and HCV co-infection respectively were 13% and 3.6% [19] and another cohort of 126 HIV positive individuals in Mekelle, Ethiopia 9.2% were co-infected with HCV [20]. These prevalence values are higher than our observation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Highly active antiretroviral therapy (HAART) has improved survival of human immunodeficiency virus (HIV) patients. Concurrent morbidities from liver diseases among these patients have also been observed due to co-infection with hepatitis B and C viruses (HBV and HCV). HAART reduces liver-associated morbidities and mortalities in such patients. Unfortunately free testing of HBV and HCV are not provided alongside free HIV testing and treatment in Nigeria. We assessed the seroprevalence of HBV and HCV among HIV patients presenting for treatment in our center. This prospective study of adult patients with HIV/AIDS assessed the seroprevalence of HBV and HCV co-infection using a 19-item questionnaire and collection of 2ml venous blood for hepatitis B surface antigens (HBsAg) and anti-HCV antibodies. All previously diagnosed HIV patients of the unit were excluded from the study. Of the 404 patients, 69.2% were females while 30.8% were males. Married participants were 59.6%, 25.3% were single and 15% were previously married. A large proportion (69%) of patients were farmers, artisans and traders. Most had some formal education; secondary (55.3%), primary 27.3%, tertiary 13.8%. HBsAg positive participants were 9 (2.2%) while 3 (0.7%) were positive for HCV. No participant had triple infection of HIV/HBV/HCV. Seroprevalence of HBV and HCV is low among HIV patients in Orlu. However there is a need for HBV and HCV testing of all HIV positive patients to reduce morbidities and mortalities from liver diseases.
    Pan African Medical Journal 09/2013; 16:7. DOI:10.11604/pamj.2013.16.7.3077
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction La prévalence du virus de l’hépatite C (VHC) n’est pas bien connue au Burundi. Des études parcellaires rapportent des taux variés. Aucune étude couvrant le territoire national n’avait été faite. But Déterminer la prévalence des anticorps anti virus de l’hépatite C (AcVHC) au Burundi. Méthodes Lors d’une enquête nationale de séroprévalence du VIH menée par le CEFORMI du CHU Kamenge en 2002, entre 2 et 4 ml de sérum et de plasma ont été décantés pour chaque échantillon puis conservés à -20°C pour usage ultérieur. Nous avons repris et analysé ces échantillons. Résultats Au total, 5569 individus ont été enrôlées, 2660 (47,8%) hommes et 2909 (52,2%) femmes. L’âge moyen était de 31±15 ans avec une médiane de 28 ans. Au niveau national, la prévalence globale des AcVHC était de 8,2%. Elle était de 8,3% chez l’homme et de 8,1% chez la femme. Selon les strates, la prévalence était de 10% en zone urbaine, de 9,1% en zone semi-urbaine et de 7,4% en zone rural. La co-infection avec le VIH était de 1,3% en zone urbaine, de 0,8% en zone semi-urbaine et de 0,1% en zone rurale. Conclusion La prévalence du virus de l’hépatite C est estimée à 8,2%. Elle est parmi les plus élevées en Afrique.
    Journal Africain d?Hépato-Gastroentérologie 03/2014; 8(1):25-28. DOI:10.1007/s12157-014-0511-6
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Human immunodeficiency virus (HIV), Hepatitis B (HBV) and Hepatitis C (HCV) are blood-borne viruses with potentially shared routes of transmission. In high-income settings, the impact of antiretroviral therapy (ART) on survival has unmasked chronic liver disease from viral hepatitis B or hepatitis C as a leading cause of morbidity and mortality in individuals with HIV infection. It is now feared that progressive liver disease may threaten the success of ART programmes in developing countries, where HCV or HBV testing and monitoring are not yet systematic among HIV-infected patients and ART use is generally blind to these co-infections. We set out to review recent data from Sub-Saharan Africa, in order to build a detailed and up-to-date picture of the epidemiology and emerging impact of HBV and HCV coinfection in countries at the heart of the HIV pandemic. There is a preponderance of HIV/HBV coinfection compared to HIV/HCV in this region, and significant caveats exist regarding the accuracy of published HCV seroprevalence surveys. Morbidity and mortality of coinfection is significant, and may be further enhanced in African populations due to the influence of host, viral and environmental factors. Careful scrutiny of the coinfection problem is vital to inform an approach to directing resources, planning public health initiatives, providing clinical care, and guiding future research.
    Journal of Clinical Virology 09/2014; 61(1). DOI:10.1016/j.jcv.2014.05.018 · 3.02 Impact Factor
Show more